Showing 2040 results
-
Press release /Remibrutinib, a highly selective oral BTKi, has potential to be first targeted therapy approved for CSU in Europe Improvements with remibrutinib observed as early as Week 1 in REMIX 1 & 2, with…
-
Featured News /
Developing treatments for blood cancers and serious blood disorders is important, but it is only part of the equation. We also need to help ensure those who may need our therapies can get them.
-
Statement /
-
Media Library / -
Media Library / -
Media Library / -
Press release /Clearance of critical milestone expands capability for production of gene therapies, starting with Zolgensma® Basel, April 5, 2022 – Novartis today announced the U.S. Food and Drug Administration (…
-
Story /A conversation with Joachim Momm, head of a Novartis manufacturing site that will be helping to produce Pfizer-BioNTech vaccine doses.
-
Press release /Agreement will bring Alnylam’s proprietary siRNA technology to bear on liver target identified by Novartis researchers Novartis and Alnylam have agreed to collaborate on discovery and development of…
-
Press release /Gilbert Ghostine, CEO of the Swiss multi-national fragrances business Firmenich appointed Chairman-Designate of the future Sandoz BoardMr Ghostine to begin role as Sandoz Chairman following the spin-…